Antigenics Inc. (New York) Says Cancer Vaccine Study Shows Promise

Oct 25 (Reuters) - Antigenics Inc (AGEN.O: Quote, Profile, Research) said its potential cancer vaccine Oncophage showed promise in a mid-phase trial on 12 patients.

MORE ON THIS TOPIC